Replies to post #5743 on THE WOOF OF WALL STREET

[BottomBounce]

BCRX global phase 3 APeX. Trial-met-primary-endpoint of a reduction in the rate of HAE attacks for berotralstat 150 mg compared to placebo during the 24-week period (p=0.003). Berotralstat was safe and generally well-tolerated in the trial. https://finance.yahoo.com/news/allergy-publishes-results-biocryst-apex-120000777.html

[BottomBounce]

$GSAT going up